Cardiorenal Syndrome Type 1: Definition, Etiopathogenesis, Diagnostics and Treatment

1. Ronco C, McCullough PA, Anker SD, et al. Acute Dialysis Quality Initiative (ADQI) Consensus Group. Cardiorenal syndromes: an executive summary from the Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 2010; 165: 54–67.10.1159/00031374520427956Search in Google Scholar

2. Hata N, Yokoyama S, Shinada T, et al. Acute kidney injury and outcomes in acute decompensated heart failure: evaluation of the RIFLE criteria in an acutely ill heart failure population. Eur J Heart Fail 2010; 12: 32–7.10.1093/eurjhf/hfp16920023042Search in Google Scholar

3. Ronco C, Haapio M, House AA, Anaveker N, Bellomo R. Cardiorenal Syndrome. J Am Coll Cardiol 2008; 52(19): 1527-39.10.1016/j.jacc.2008.07.05119007588Open DOISearch in Google Scholar

4. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34(5): 957-62.10.1007/s00134-008-1017-818251008Search in Google Scholar

5. Ronco C, Chionh C-Y, Haapio M, Anavekar NS, House A, Bellomo R. The Cardiorenal Syndrome. Blood Purif 2009; 27(1): 114-26.10.1159/00016701819169027Search in Google Scholar

6. Poskurica M. Cardiorenal syndrome: definition, ethyopatogenesis, clinical manifestations, diagnostic, prevention and therapy. In: Acure renal failure: prevention, dijagnostic, therapy. Poskurica M. Ed : 77-106. Medical faculty Kragujevac, Inter print Kragujevac, Kragujevac, 2009. (in Serbian)Search in Google Scholar

7. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal Syndrome. In: Cardionephrology 4. Radenković S. Ed.: 13-29. GIP “PUNTA“, Niš, 2009.Search in Google Scholar

8. Ronco C, McCullough PA, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardiorenal Syndromes: An Executive Summary from the Consensus Conference of the Acute Dialysis Quality Initiative(ADQI). In: Cardiorenal Syndromes in Critical Care. Ronco C, Bellomo R, McCullough PA (eds). Contrib Nephrol. Basel, Karger, 2010; 165: 54-67.10.1159/isbn.978-3-8055-9473-8Search in Google Scholar

9. Teerlink JR. Diagnosis and Management of Acute Heart Failure. In: Braunwald’s Heart Disease. Libby P, Bonow RO, Mann Douglas L, Zipes DP, Braunwald E. (eds). Philadelphia: Saunders Elsevier, 2008: 583-610.Search in Google Scholar

10. Petrović D, Jagić N, Miloradović V, Nikolić A, Stojimirović B. Cardiorenal syndrome - definition, classification and basic principles of therapy. Ser J Exp Clin Res 2010; 11(2): 67-71.Search in Google Scholar

11. Ronco C, Cicoira M, McCullough P A. Cardiorenal syndrome type 1: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure. J Am Coll Cardiol 2012; 60: 1031–42.10.1016/j.jacc.2012.01.07722840531Search in Google Scholar

12. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589–96.10.1016/j.jacc.2008.05.068285696019215833Search in Google Scholar

13. Costanzo MR, Jessup M. The cardiorenal syndrome: do we need a change of strategy or a change of tactics? J Am Coll Cardiol. 2009; 53 (7): 597-9.10.1016/j.jacc.2008.11.01219215834Search in Google Scholar

14. Kopp UC, DiBona GF. Neural regulation of renin secretion. Semin Nephrol 1993; 13: 543–51.Search in Google Scholar

15. Haase M, Müller C, Damman K, Murray PT, Kellum JA, Ronco C, et al. Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: Workgroup statements from the eleventh consensus conference of the acute dialysis quality initiative (ADQI). Contrib Nephrol 2013; 182 : 99–116.10.1159/00034996923689658Search in Google Scholar

16. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007; 4: 444–54.10.1038/ncpcardio0938Open DOISearch in Google Scholar

17. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol 2005; 95: 3C–8C.10.1016/j.amjcard.2005.03.006Search in Google Scholar

18. Mantovani A, Garlanda C, Bottazzi BP, et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 2006; 45: 326–30.10.1016/j.vph.2006.08.011Search in Google Scholar

19. Milo O, Cotter G, Kaluski E, et al. Inflammatory and neurohormonal activation in cardiogenic pulmonary edema: implications on the pathogenesis . and outcome of acute ischemic versus non-ischemic acute heart failure. Am J Cardiol 2003; 92: 222–6.10.1016/S0002-9149(03)00545-9Open DOISearch in Google Scholar

20. Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol 2005; 95: 17C–23C, discussion 38C–40C.10.1016/j.amjcard.2005.03.008Search in Google Scholar

21. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascularmortality: Is C-reactive protein the missing link? Kidney Int 2001; 59: 407-14.Search in Google Scholar

22. Pastori S, Virzì GM, Brocca A, de Cal M, Clementi A, Vescovo G, et al. Cardiorenal syndrome type 1: a defective regulation of monocyte apoptosis induced by proinflammatory and proapoptotic factors. Cardiorenal Med 2015; 5(2): 105–15.10.1159/000371898Search in Google Scholar

23. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51(15): 1419-28.10.1016/j.jacc.2007.12.035Search in Google Scholar

24. Diez C, Haneya A, Brünger F, et al. Minimized extracorporeal circulation cannot prevent acute kidney injury but attenuates early renal dysfunction after coronary bypass grafting. ASAIO J 2009; 55(6): 602–7.10.1097/MAT.0b013e3181bbcd3eOpen DOISearch in Google Scholar

25. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997; 103 : 368 –75.10.1016/S0002-9343(97)00150-2Search in Google Scholar

26. Metra M, Nodari S, Parrinello G, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. European Journal of Heart Failure 2008; 10(2): 188–95.10.1016/j.ejheart.2008.01.01118279773Search in Google Scholar

27. Cheng H, Chen YP. Clinical prediction scores for type 1 cardiorenal syndrome derived and validated in chinese cohorts. Cardiorenal Med 2015; 5(1): 12–9.10.1159/000369479432733725759696Search in Google Scholar

28. Forman DE, Butler J, Wang Y, et al: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43: 61–7.10.1016/j.jacc.2003.07.03114715185Search in Google Scholar

29. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44: 1393–9.Search in Google Scholar

30. Petrović D. Akutno oštećenje bubrega: etiologija, dijagnostika i lečenje. Medicinska Istraživanja 2011; 45(3): 7-13.Search in Google Scholar

31. Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J Card Fail. 2010; 16: 49–54.10.1016/j.cardfail.2009.07.003285695220123318Search in Google Scholar

32. Pfister R, Müller-Ehmsen J, Hagemeister J, Hellmich M, Erdmann E, Schneider CA. NT-pro-BNP predicts worsening renal function in patients with chronic systolic heart failure. Intern Med J 2011; 41 (6): 467-72.10.1111/j.1445-5994.2010.02203.x20214692Open DOISearch in Google Scholar

33. Petrović D, Milovanović D, Miloradović V, et al. Cardiorenal syndrome type 2: Etiopathogenesis, diagnosis and therapy. Med Cas 2012; 46(1): 30–4.Search in Google Scholar

34. Maisel AS, Katz N, Hillege HL, et al. and for the Acute Dialysis Quality Initiative (ADQI) consensus group. Biomarkers in kidney and Heart disease. Nephrol Dial Transplant 2011; 26: 62-74.10.1093/ndt/gfq64720978142Search in Google Scholar

35. Shrestha K, Borowski AG, Troughton RW, Thomas JD, Klein AL, Tang WH. Renal dysfunction is a stronger determinant of system ic neutrophil gelatinase-associated lipocalin levels than myocardial dysfunction in systolic heart failure. J Card Fail 2011; 17: 472–8.10.1016/j.cardfail.2011.02.003310524721624735Search in Google Scholar

36. Campbell CY, Clarke W, Park H, Haq N, Barone BB, Brotman DJ. Usefulness of cystatin C and prognosis following admission for acute heart failure. Am J Cardiol 2009; 104: 389–92.10.1016/j.amjcard.2009.03.05919616673Open DOISearch in Google Scholar

37. Taglieri N, Fernandez-Berges DJ, Koenig W, et al. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis 2010; 209: 300-5.10.1016/j.atherosclerosis.2009.09.02219819453Search in Google Scholar

38. Ismail Y, Kasmikha Z, Green HL, McCullough PA. Cardiorenal syndrome type 1: epidemiology, pathophysiology, and treatment. Semin Nephrol Elsevier 2012; 32(1): 18–25.10.1016/j.semnephrol.2011.11.00322365158Search in Google Scholar

39. Petrović D, Jagić N, Miloradović V, Nikolić A, Poskurica M, Stojimirović B. Kardio-renalni sindrom u akutnoj dekompenzaciji hronične kongestivne srčane slabosti. U: Kardionefrologija 5. Radenković S, ed. Nis: GIP PUNTA, 2011: 117-26.Search in Google Scholar

40. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364(9): 797–805.10.1056/NEJMoa1005419341235621366472Search in Google Scholar

41. Ismail Y, Kasmikha Z, Green HL, McCullough PA. Cardio-renal syndrome type 1: epidemiology, pathophysiology, and treatment. Semin Nephrol. Elsevier 2012; 32 (1): 18–25.Search in Google Scholar

42. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int Suppl 2005; 68 (99): S57–65.10.1111/j.1523-1755.2005.09911.x16336578Search in Google Scholar

43. Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 2009; 4: 2013-26.10.2215/CJN.0315050919965544Search in Google Scholar

44. Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S. The Effect of KW-3902, an Adenosine A1 Receptor Antagonist, on Renal Function and Renal Plasma Flow in Ambulatory Patients With Heart Failure and Renal Impairment. J Card Fail 2007; 13(8): 609–17.10.1016/j.cardfail.2007.08.00617923351Search in Google Scholar

45. Weatherley BD, Cotter G, Dittrich HC, et al. Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function. J Card Fail Elsevier Inc 2010; 16(1): 25–35.10.1016/j.cardfail.2009.10.02520123315Open DOISearch in Google Scholar

46. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. American Medical Association 2007; 297(12): 1319–31.10.1001/jama.297.12.131917384437Search in Google Scholar

47. Udelson JE, Smith WB, Hendrix GH, et al. Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure. Circulation 2001; 104(20): 2417–23.10.1161/hc4501.09931311705818Open DOISearch in Google Scholar

48. Srdjan L, Dejan P. Prevention of acute renal injury in intensive care units. Med Cas 2012; 46(2): 100–4.10.5937/mckg46-1384Search in Google Scholar

49. O’Connor CM, Starling RC, Hernandez F, et al. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. N Engl J Med 2011; 365(1): 32–43.10.1056/NEJMoa110017121732835Search in Google Scholar

50. Lüss H, Mitrovic V, Seferovic PM, et al. Renal effects of ularitide in patients with decompensated heart failure. Am Heart J. Elsevier 2008; 155(6): 1012.e1–8.10.1016/j.ahj.2008.02.01118513512Search in Google Scholar

51. Dahle TG, Sobotka PA, Boyle AJ. A practical guide for ultrafiltration in acute decompensated heart failure. Congst Heart Failure 2008; 14: 83-8.10.1111/j.1751-7133.2008.07649.x18401216Search in Google Scholar

52. Bart BA. Congestion in congestive heart failure: ultrafiltration is the only rational initial treatment of volume overload in decompensated heart failure. Circ Heart Fail 2009; 2: 499-504.10.1161/CIRCHEARTFAILURE.109.86338119808381Search in Google Scholar

53. Udani SM, Murray PT. The use of renal replacement therapy in acute decompensated heart failure. Semin Dial 2009; 22: 173-9.10.1111/j.1525-139X.2008.00542.x19426424Search in Google Scholar

54. Costanzo MA, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 675-83.10.1016/j.jacc.2006.07.07317291932Search in Google Scholar

55. Rogers HL, Marshall J, Bock J, et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J Card Fail. Elsevier 2008; 14(1): 1–5.10.1016/j.cardfail.2007.09.00718226766Open DOISearch in Google Scholar

56. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367(24): 2296–304.10.1056/NEJMoa1210357369047223131078Search in Google Scholar

57. Prins KW, Wille KM, Tallaj JA, Tolwani AJ. Assessing continuous renal replacement therapy as a rescue strategy in cardiorenal syndrome 1. Clin Kidney J 2015; 8(1): 87–92.10.1093/ckj/sfu123431042625713716Search in Google Scholar

58. Patarroyo M, Wehbe E, Hanna M, et al. Cardiorenal Outcomes After Slow Continuous Ultrafiltration Therapy in Refractory Patients With Advanced Decompensated Heart Failure. J Am Coll Cardiol 2012; 60(19): 1906–12.10.1016/j.jacc.2012.08.95723062527Open DOISearch in Google Scholar

59. Nohria A, Hasselblad C, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008; 51: 1268–74.10.1016/j.jacc.2007.08.07218371557Search in Google Scholar

60. Núñez J, González M, Miñana G, et al. Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure. Eur J Heart Fail. 2012; 14(5): 540-8.10.1093/eurjhf/hfs01322327061Search in Google Scholar

61. Kunin M, Arad M, Dinour D, Freimark D, Holtzman E.J. Peritoneal Dialysis in Patients with Refractory Congestive Heart Failure: Potential Prognostic Factors. Blood Purif 2013; 35: 285-94.10.1159/00035120223712042Search in Google Scholar

62. Daniela, Marina BB, Cassiana G, André B. Peritoneal Dialysis in Acute Kidney Injury: Trends in the Outcome across Time Periods. PLoS One. 2015; 10(5): e0126436.10.1371/journal.pone.0126436442862225965868Search in Google Scholar